Alkermes PLC (ALKS) Position Increased by Creative Planning
Creative Planning raised its position in shares of Alkermes PLC (NASDAQ:ALKS) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,877 shares of the company’s stock after buying an additional 865 shares during the period. Creative Planning’s holdings in Alkermes PLC were worth $1,094,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in ALKS. BlackRock Inc. raised its position in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock worth $602,115,000 after buying an additional 10,121,839 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock worth $459,608,000 after buying an additional 1,480,273 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Alkermes PLC by 220.0% in the first quarter. Janus Capital Management LLC now owns 1,658,928 shares of the company’s stock worth $97,045,000 after buying an additional 1,140,555 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Alkermes PLC by 40.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,857,077 shares of the company’s stock worth $167,138,000 after buying an additional 820,355 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Alkermes PLC during the fourth quarter worth about $44,274,000. 97.24% of the stock is currently owned by institutional investors.
Shares of Alkermes PLC (NASDAQ ALKS) opened at 57.62 on Thursday. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40. The company’s 50 day moving average price is $58.62 and its 200 day moving average price is $57.52. The firm’s market capitalization is $8.83 billion.
Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes PLC had a negative return on equity of 9.76% and a negative net margin of 25.61%. The firm had revenue of $191.80 million during the quarter, compared to the consensus estimate of $195.79 million. During the same quarter in the prior year, the business posted ($0.16) EPS. Alkermes PLC’s revenue was up 22.3% compared to the same quarter last year. Analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current year.
ALKS has been the topic of a number of recent analyst reports. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a research report on Monday, April 3rd. Credit Suisse Group reaffirmed a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a research report on Wednesday, June 7th. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research report on Friday, April 28th. Finally, Leerink Swann lowered Alkermes PLC from an “outperform” rating to a “market perform” rating and cut their target price for the company from $68.00 to $61.00 in a research report on Tuesday, June 13th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $62.55.
In related news, Director Richard F. Pops sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $57.29, for a total transaction of $1,432,250.00. Following the completion of the transaction, the director now owns 655,406 shares in the company, valued at approximately $37,548,209.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Shane Cooke sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $60.33, for a total value of $603,300.00. Following the transaction, the insider now owns 84,708 shares of the company’s stock, valued at approximately $5,110,433.64. The disclosure for this sale can be found here. Insiders have sold a total of 139,500 shares of company stock valued at $8,086,675 in the last 90 days. 5.34% of the stock is owned by corporate insiders.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.